Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 7Withdrawn 4Terminated 3Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Breast 3Thoracic 2Genitourinary 2Gastrointestinal 1

Conditions

Breast Neoplasms 55Neoplasm Metastasis 5Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Endometrial Neoplasms 2Colorectal Neoplasms 2Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms by Site 1Neoplasms 1Malignant Neoplasms of Female Genital Organs 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Liposarcoma 1Hormone Receptor Positive Breast Carcinoma 1Head and Neck Neoplasms 1HR-positive, HER2-negative Breast Neoplasms 1HER2-positive Metastatic Breast Cancer 1Genital Neoplasms, Female 1Genetic Diseases, Inborn 1Estrogen Receptor Positive Breast Cancer 1ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer 1Disease Progression 1

Interventions

pembrolizumab 24Carboplatin 21Paclitaxel 20olaparib 19Magnetic Resonance Spectroscopy 14Bevacizumab 14Cyclophosphamide 12Specimen Handling 11Nivolumab 11Gemcitabine 11Taxes 10niraparib 8Cisplatin 8Biopsy 8liposomal doxorubicin 7fludarabine 7Surveys and Questionnaires 6Immunoglobulin G 6Doxorubicin 6Disulfides 6durvalumab 5palbociclib 4oregovomab 4X-Rays 4Ipilimumab 4mirvetuximab soravtansine 3ipatasertib 3defactinib 3cediranib 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Ovarian Neoplasms × Fulvestrant × Clear all
NCT06257264 2026-06-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BeOne Medicines

Phase 1 Active not recruiting
103 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07038369 2026-06-03

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Atavistik Bio, Inc

Phase 1 Active not recruiting
134 enrolled
BreastGenitourinaryGynecologic

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04553133 2026-05-06

PF-07104091 as a Single Agent and in Combination Therapy

Pfizer

Phase 2 Active not recruiting
157 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡